Skip to content
Meta-analysis Open access

Statins use and prognosis in lung cancer patients treated with immune checkpoint inhibitors: evidence from a meta-analysis

Sep 2026 · Frontiers in Immunology · Vol 17 · 0 citations · 50 references
Medicine

TL;DR

A meta-analysis indicates that statin use is associated with significantly prolonged OS and PFS in lung cancer patients receiving ICIs, suggesting a potential role for statins in augmenting ICI efficacy.

Abstract

Background Lung cancer remains one of the most common and lethal malignancies worldwide. The advent of immune checkpoint inhibitors (ICIs) has substantially improved survival outcomes in patients with advanced disease; nevertheless, a considerable proportion of patients exhibit suboptimal responses to ICI monotherapy. In recent years, statins have garnered attention for their potential immunomodulatory and anti-inflammatory properties. Preclinical evidence suggests that statins may enhance antitumor immune responses by modulating the tumor microenvironment and facilitating antigen presentation. However, existing clinical data remain inconclusive regarding whether statin use influences prognosis in lung cancer patients receiving ICIs. Accordingly, this meta-analysis was undertaken to evaluate the impact of statin use on survival outcomes in this patient population, with the aim of informing clinical decision-making regarding combination strategies. Methods We systematically searched PubMed, Embase, the Cochrane Library, and Web of Science for clinical studies published from database inception to June 2026 that examined the association between statin use and outcomes in lung cancer patients treated with ICIs. Two investigators independently screened the literature, extracted data, and assessed the risk of bias using the Newcastle-Ottawa Scale (NOS). The primary endpoints were overall survival (OS) and progression-free survival (PFS). A meta-analysis was performed using Stata 15.0 software. Results Twelve studies comprising 5,156 participants were included. Pooled analysis demonstrated that statin use was associated with significantly improved OS (HR = 0.76, 95% CI (0.63, 0.91), P = 0.003) and PFS (HR = 0.82, 95% CI (0.69, 0.96), P = 0.017). Subgroup analyses revealed that the survival benefit remained significant for both OS and PFS in multivariate-adjusted estimates. In univariate analyses and in larger studies (n > 500), the benefits did not attain statistical significance. Geographically, statins significantly improved OS in non-Asian populations, whereas the PFS benefit in these populations did not reach significance. Conclusions This meta-analysis indicates that statin use is associated with significantly prolonged OS and PFS in lung cancer patients receiving ICIs, suggesting a potential role for statins in augmenting ICI efficacy. However, given that the included studies were predominantly retrospective observational designs, these findings should be interpreted with caution. Prospective, large-scale randomized controlled trials are warranted to confirm the survival benefits of combined statin and ICI therapy and to define the optimal timing and target population for such combination. Systematic review registration https://www.crd.york.ac.uk/PROSPERO/, identifier CRD420261420311

Read PDF

Similar papers

Review Open access Oct 2026

Recent advances and future perspectives in non-small cell lung cancer immunotherapy

The introduction of immune checkpoint inhibitors has transformed therapeutic strategies for non-small cell lung cancer; however, the generalisation of data regarding their molecular mechanisms of action and predictors of therapeutic efficacy remains an important challenge. The aim of this study was to conduct a compreh...

Нургуль Адылгазиевна Садырова, Zhanibek Muratov, A.Sh. Tashpolotova et al. · 0 citations
Review Open access Oct 2026

Antibiotics and outcomes of cancer immunotherapy: An updated meta-analysis and clinical applications.

The gut microbiome is a modifiable determinant of response to immune checkpoint inhibitors (ICI), positioning antibiotic exposure as a critical yet under-recognized risk factor for worse survival outcomes in immuno-oncology. As nearly 30% of ICI-treated patients receive antibiotics and indications of cancer immunothera...

Serena Porcari, L. Bolte, J. Björk et al. · 0 citations
#software testing Meta-analysis Open access Oct 2026

Association between antibiotic exposure and survival outcomes in hepatocellular carcinoma patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis

For HCC patients receiving ICI therapy, antibiotic exposure was significantly associated with reduced OS, and a significant association with poorer PFS was observed, although this finding was not robust in sensitivity analyses and should therefore be interpreted with caution.

Shuai-Hang Chen, Shan-Shan Chen, Yuan-Qiang Li et al. · 0 citations
Review Open access Oct 2026

Type 1 diabetes mellitus during immune checkpoint inhibitor therapy in cancer patients

The development of immune checkpoint inhibitors (ICIs) has led to significant changes in the treatment strategies for malignant tumors. Results from numerous randomized trials of this class of drugs, alongside their widespread adoption in clinical practice, have demonstrated superior therapeutic efficacy in patients wi...

R. Orlova, I. V. Gerk, I. Itkin et al. · 0 citations
Open access Sep 2026

Smoking cessation improves the prognosis of cancer patients and is comparable to the effectiveness of innovative antitumor therapy

Smoking not only leads to the development of cancer but also worsens the prognosis of cancer patients. Objective: to study the impact of smoking cessation on the prognosis of patients diagnosed with non-small cell lung cancer (NSCLC) and clear cell renal cell carcinoma (ccRCC), and to compare these results with the...

D. Zaridze, A. Mukeria, O. Shangina · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.